If the European Commission approves this treatment, it'll be the first HER2-targeted agent for HER2-positive biliary tract cancer available to patients in the EU.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion ...

Detailed price information for Jazz Pharma Plc (JAZZ-Q) from The Globe and Mail including charting and trades.

Epilepsy Alliance Florida will host its annual Gainesville Walk the Talk for Epilepsy is slated for Saturday, April 26, at ...

Jazz Pharmaceuticals has acquired Chimerix Inc. for approximately $935 million in cash. Chimerix is now a wholly owned subsidiary of Jazz.

Addition of dordaviprone strengthens Jazz's late-stage oncology pipeline and reinforces commitment to addressing rare diseases with significant unmet need - DUBLIN, April 21, 2025 /PRNewswire/ ...

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced the successful completion of its acquisition of Chimerix, Inc. ("Chimerix") for approximately $935 million in cash.

Sanofi SNY and partner Regeneron REGN announced that the FDA approved Dupixent (dupilumab) for the treatment of chronic ...